8A-PDHQ

From Wikipedia, the free encyclopedia
Jump to: navigation, search
8A-PDHQ
Phenyldecahydroquinoline.svg
Systematic (IUPAC) name
8a-phenyldecahydroquinoline
Clinical data
Legal status ?
Identifiers
CAS number 131556-11-1 N
ATC code ?
PubChem CID 131397
ChemSpider 116144 YesY
Chemical data
Formula C15H21N 
Mol. mass 215.3339 g/mol
 N (what is this?)  (verify)

8a-Phenyldecahydroquinoline (8A-PDHQ) is a high affinity NMDA antagonist developed by a team at Parke Davis in the 1950s.[1] It is a structural analog of Phencyclidine with slightly lower binding affinity than the parent compound. (-)-8a-Phenyldecahydroquinoline has an in vivo potency comparable to that of (+)-MK-801.[2][3]

References[edit]

  1. ^ US Patent 3035059
  2. ^ Chen C, Kozikowski AP, Wood PL, Reynolds IJ, Ball RG, Pang YP (1992). "Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency". Journal of Medicinal Chemistry 35 (9): 1634–8. doi:10.1021/jm00087a020. PMID 1315871. 
  3. ^ Elhallaoui M, Laguerre M, Carpy A, Ouazzani FC (2002). "Molecular modeling of noncompetitive antagonists of the NMDA receptor: proposal of a pharmacophore and a description of the interaction mode". J Mol Model 8 (2): 65–72. doi:10.1007/s00894-001-0067-4. PMID 12032600.